Quick Answer: PFAS litigation is expected to expand rapidly in 2026 as federal regulations tighten and lawsuits over firefighting foam, water contamination, and health impacts continue nationwide.

Litigation over per- and polyfluoroalkyl substances (PFAS), often called “forever chemicals,” continues to expand rapidly across U.S. courts, regulatory agencies, and state legislatures. As scientific evidence linking PFAS exposure to serious health risks grows and federal and state regulation tightens, corporations, municipalities, and individuals face an increasingly complex legal landscape.

This updated overview explains the major PFAS lawsuits and legal developments shaping 2026 and beyond, the key legal theories driving claims, and what plaintiffs and defendants can expect as this litigation matures.

PFAS are a large group of synthetic chemicals used for decades in firefighting foams, nonstick coatings, textiles, industrial processes, and other consumer and commercial products. Chemically stable and resistant to breakdown, PFAS persist in the environment and human body, raising serious health and ecological concerns.

The two most studied PFAS compounds, PFOA and PFOS, have been phased out in U.S. manufacturing, but thousands of related compounds remain in use.

Key characteristics of PFAS:

• Highly persistent (“forever chemicals”)
• Bioaccumulative in humans and wildlife
• Detected in drinking water, soil, and food systems

Scientific studies and government health assessments continue to link PFAS exposure with a wide range of conditions, including:

• Certain cancers (kidney, testicular)
• Immune system suppression
• Thyroid disease
• Elevated cholesterol
• Liver damage
• Reproductive and developmental effects

In 2024–2025, the U.S. Environmental Protection Agency (EPA) finalized stricter drinking water limits for several PFAS compounds, which has intensified litigation by providing a more concrete regulatory baseline for plaintiffs.

Common routes of human and environmental exposure include:

• Contaminated drinking water near manufacturing or military sites
• AFFF firefighting foams used at airports, training grounds, and bases
• Industrial discharges and runoff
• Household products and packaging

Because PFAS can travel long distances through groundwater and air, exposure often occurs far from the initial release site, complicating causation and liability analysis.

In late 2023 and into 2024, the EPA issued stringent health advisories and enforceable maximum contaminant levels (MCLs) for multiple PFAS compounds in public water systems. These regulatory changes:

• Provide evidence of manufacturer knowledge of harm
• Support claims of negligence, failure to warn, and public nuisance
• Increase the potential damages recoverable by municipalities and water authorities

Several states — including California, New York, New Jersey, and Massachusetts — have also adopted their own PFAS drinking water standards and chemical bans, strengthening regulatory overlap with federal limits.

In 2025, many jurisdictions have implemented:

• bans on certain PFAS in consumer products
• restrictions on firefighting foams
• requirements for PFAS monitoring in water systems

These laws create additional regulatory bases for liability and are frequently cited in litigation as evidence of unreasonable conduct.

The Aqueous Film-Forming Foam (AFFF) MDL (often referenced as MDL No. 2873) remains one of the central battlegrounds in PFAS litigation. The MDL consolidates thousands of cases brought by:

• Firefighters and veteran personnel
• Municipalities and water utilities
• Counties and states

These plaintiffs allege that manufacturers knew or should have known their foams would contaminate water supplies yet failed to warn first responders and the public.

This MDL continues to see:

• Bellwether trials
• Expanded discovery into internal corporate documents
• Settlement negotiations that may influence future individual claims

This lawsuit is currently open to join for firefighters, military veterans and their dependents.

States such as California, Michigan, New York and, recently, Texas have filed lawsuits against PFAS manufacturers, seeking damages for environmental cleanup and healthcare costs.

Public water systems across the U.S. have filed or are pursuing claims seeking reimbursement for:

• Treatment and filtration system upgrades
• Long-term monitoring programs
• Capital costs associated with PFAS compliance

Many of these suits assert causes of action under:

• Public nuisance
• Strict liability
• Negligence
• State environmental protection statutes

A growing body of personal injury claims alleges that PFAS exposure caused or significantly contributed to cancer diagnoses or other serious health conditions. These cases often incorporate:

• Expert medical testimony linking PFAS biomarkers to disease
• Long latency periods and ongoing injuries
• Requests for court-ordered medical monitoring funds

Given the long timespan of exposure and discovery, these claims are frequently litigated over causation and admissibility of expert evidence.

Beyond water systems and first responders, individual plaintiffs have filed lawsuits against manufacturers of PFAS-containing products, asserting:

• Defective design or formulation
• Failure to warn
• Fraudulent concealment of health risks

These product liability claims seek damages for personal harm, medical expenses, and in some cases punitive damages.

PFAS litigation often combines multiple legal theories, including:

• Product Liability: Claims that PFAS chemicals or products were defectively designed or marketed without adequate warnings.
• Negligence: Asserting that manufacturers failed to exercise reasonable care given known or knowable risks.
• Public Nuisance: Legal action by municipalities alleging that PFAS contamination interferes with public rights and requires abatement.
• Medical Monitoring: Claims for ongoing medical testing due to increased risk of disease from exposure.
• Regulatory Violation Evidence: Use of EPA and state standards to demonstrate breach of duty or foreseeability of harm.

PFAS cases often present complex issues around:

1. Causation: Demonstrating a direct link between PFAS and specific health outcomes can be difficult due to latency and multifactorial health conditions.
2. Identification of Responsible Parties: Commercial PFAS supply chains can involve multiple manufacturers, distributors, and formulators.
3. Statutes of Limitation: Because exposure and diagnosis may be separated by decades, timely filing and tolling doctrines are frequently litigated.
4. Bankruptcy and Corporate Structure: Corporate defendants may seek chapter 11 protections or restructure to limit liability exposure.

Litigation trends through 2026 are expected to include:

• Expansion of MDLs and coordinated state actions
• Increased personal injury filings as more data links PFAS to specific diseases
• Additional settlements that resolve broad categories of claims
• Legislative proposals for federal compensation funds
• Greater use of regulatory standards in civil liability arguments

Potential plaintiffs include:

• Residents whose drinking water contains PFAS above regulatory limits
• First responders exposed to firefighting foams
• Municipal water authorities requiring PFAS treatment solutions
• Workers with documented occupational PFAS exposure
• Individuals diagnosed with PFAS-associated health conditions

Eligibility generally depends on:

1. Proof of exposure
2. Scientific evidence of related health effects
3. Compliance with state notice and filing requirements

PFAS litigation is one of the most active and legally complex arenas in U.S. tort and environmental law. With evolving regulatory standards, expanding scientific evidence, and growing public awareness, litigation in 2026 and beyond will likely continue to challenge defendants while creating new opportunities for plaintiffs to seek compensation and remediation.

Understanding the current landscape, common legal theories, and litigation trends is critical for practitioners, public entities, affected individuals, and policymakers.